# Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions

Study · id `cardio:ct-nct05096442` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05096442](<https://clinicaltrials.gov/study/NCT05096442>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05096442

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 204 participants.

## Technical summary

Registry record NCT05096442. Randomized; single masking; primary purpose treatment. Start 2021-09-30 (actual); primary completion 2023-06-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 204 participants (enrolled count; ClinicalTrials.gov record NCT05096442, source copy `cardio:ctgov-nct05096442-2024-05-17`, retrieved 2026-10-26)
- Started: 2021-09-30 (actual) (ClinicalTrials.gov record NCT05096442, source copy `cardio:ctgov-nct05096442-2024-05-17`, retrieved 2026-10-26)
- Primary completion: 2023-06-28 (actual) (ClinicalTrials.gov record NCT05096442, source copy `cardio:ctgov-nct05096442-2024-05-17`, retrieved 2026-10-26)
- Completion: 2023-11-21 (actual) (ClinicalTrials.gov record NCT05096442, source copy `cardio:ctgov-nct05096442-2024-05-17`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05096442, source copy `cardio:ctgov-nct05096442-2024-05-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05096442-2024-05-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
- Condition: Coronary Artery Disease
- Intervention (Device): GENOSS® DCB
- Intervention (Device): SeQuent® Please NEO
- Lead sponsor: Genoss Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Genoss Co., Ltd. (`cardio:org-genoss-co-ltd`)

## Provenance

Content hash: 01a3e1e93c3ffa1ebe9266bf81eade9e8b490f09993b97fdc49eb61c2aaf4b9a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
